Glimepirida Stada

Glimepirida Stada is a prescription medication that contains the active ingredient glimepiride, a sulfonylurea antidiabetic agent, supplied as oral tablets. Marketed in the European Union under ATC code A10BB12, it stimulates insulin release from pancreatic beta cells to lower blood glucose in adults with type 2 diabetes mellitus, and is intended to be used together with diet and exercise as part of a personalized management plan.

Glimepirida Stada is indicated for the oral treatment of type 2 diabetes mellitus in adults when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

- As monotherapy in patients newly diagnosed with type 2 diabetes who do not achieve target glucose levels with lifestyle measures alone. - As add‑on therapy to metformin or other oral antidiabetic agents when additional glucose lowering is required. - In combination with basal insulin for patients who need further reduction in HbA1c. - For patients with stable renal function who can tolerate sulfonylureas.

The safety profile of Glimepirida Stada includes both frequently observed and less common adverse reactions.

Common: - Mild hypoglycemia manifested by shakiness, sweating, or hunger, usually occurring if a dose is taken without adequate food. - Nausea, occasional vomiting, or general abdominal discomfort. - Headache of mild to moderate intensity. - Dizziness or a sensation of light‑headedness, particularly after standing quickly.

Serious: - Severe hypoglycemia that may cause confusion, loss of consciousness, or seizures and requires immediate medical attention. - Allergic reactions including skin rash, pruritus, urticaria, or angio‑edema that may affect breathing. - Hematologic changes such as leukopenia, neutropenia, or thrombocytopenia reported in rare cases.

Before prescribing Glimepirida Stada, clinicians should evaluate several patient‑specific factors to minimize risk.

- Assess renal and hepatic function; dose adjustment may be needed in impairment. - Review history of cardiovascular disease, as sulfonylureas can affect cardiac ischemic preconditioning. - Verify that the patient is not pregnant or breastfeeding; safety data are limited. - Caution in elderly patients due to increased susceptibility to hypoglycemia. - Avoid use in patients with known hypersensitivity to glimepiride or other sulfonylureas. - Monitor for signs of hypoglycemia when initiating therapy or changing dose.

Glimepirida Stada can interact with other medicines, affecting blood glucose levels or increasing the risk of adverse events.

Avoid: - Concomitant use with other sulfonylureas or insulin that may cause additive hypoglycemia. - Strong CYP2C9 inhibitors such as fluconazole or amiodarone, which can raise glimepiride concentrations.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can reduce glucose tolerance and require closer monitoring. - Antifungal agents like itraconazole or certain macrolide antibiotics that moderately inhibit CYP2C9. - Warfarin, as glimepiride may alter INR and require more frequent coagulation monitoring.